Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 10:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 441 matching trials from the live ClinicalTrials.gov search.
Filters: "motor neuron disease" Condition: ALS Clear all
Not listed No phase listed Observational

Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy

NCT03330353
View directory record Official record
Conditions
PSP - Progressive Supranuclear Palsy, PD - Parkinson's Disease, AD - Alzheimer's Disease, ALS (Amyotrophic Lateral Sclerosis)
Interventions
Pupillometry
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 8, 2026, 10:27 PM EDT
Terminated Phase 2 Interventional

A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease

NCT04428775
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
ALZT-OP1a (cromolyn)
Drug
Lead sponsor
AZTherapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
La Jolla, California • Jacksonville, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 8, 2026, 10:27 PM EDT
Terminated Phase 1Phase 2 Interventional

Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS

NCT03334786
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Fasciculation
Interventions
FLX-787-ODT
Drug
Lead sponsor
Flex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 8, 2026, 10:27 PM EDT
Recruiting No phase listed Observational

Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

NCT03225144
View directory record Official record
Conditions
Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, Progressive Supranuclear Palsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 110 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 8, 2026, 10:27 PM EDT
Recruiting Not applicable Interventional

Spinal Cord Associative Plasticity for ALS

NCT06172621
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Spinal Cord Associative Plasticity (SCAP), Upper extremity task-oriented exercise
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 8, 2026, 10:27 PM EDT
Completed Not applicable Interventional Results available

ALS and Airway Clearance (ALSAC) Therapy

NCT04947436
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Respiratory Muscle Weakness
Interventions
High Frequency Chest Wall Oscillation, Mechanical insufflation/exsufflation
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
21 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 8, 2026, 10:27 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Exploratory Evaluation of [11C]MPC6827

NCT04575727
View directory record Official record
Conditions
Neurodegenerative Diseases, Alzheimer Disease, Amyotrophic Lateral Sclerosis
Interventions
[11C]MPC6827
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 8, 2026, 10:27 PM EDT
Active, not recruiting Phase 2 Interventional

T-regulatory Cells in ALS

NCT04055623
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections, Monthly placebo infusions + 3 times per week placebo injections
Biological · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 8, 2026, 10:27 PM EDT
Available No phase listed Expanded access

Three Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01, CNMAu8.EAP02, and CNMAu8.EAP06 for ALS

NCT05281484
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CNM-Au8
Drug
Lead sponsor
Clene Nanomedicine
Industry
Eligibility
18 Years and older
U.S. locations
16
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 8, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

Trial of Early Noninvasive Ventilation for Amyotrophic Lateral Sclerosis (ALS)

NCT00580593
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BiPAP® S/T System, sham-NIPPV
Device · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 79 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 8, 2026, 10:27 PM EDT
Completed Phase 2 Interventional

Trial of Oral Digoxin in Individuals With Amyotrophic Lateral Sclerosis (ALS)

NCT07047209
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Digoxin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Davie, Florida • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 8, 2026, 10:27 PM EDT
Terminated Not applicable Interventional Results available

Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis

NCT00537446
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
noninvasive positive pressure ventilation
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 8, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT00790582
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
lithium carbonate
Drug
Lead sponsor
Forbes Norris MDA/ALS Research Center
Other
Eligibility
21 Years to 80 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 8, 2026, 10:27 PM EDT
Completed No phase listed Observational

Genomic Translation for Amyotrophic Lateral Sclerosis Care

NCT02795897
View directory record Official record
Conditions
ALS
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • Ann Arbor, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 8, 2026, 10:27 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

NCT06100276
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AMT-162
Drug
Lead sponsor
UniQure Biopharma B.V.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
11
States / cities
Phoenix, Arizona • Irvine, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 8, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALS

NCT05039099
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AP-101, Placebo
Drug
Lead sponsor
AL-S Pharma
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 8, 2026, 10:27 PM EDT
Completed Not applicable Interventional

Mechanical Insufflation in the Philadelphia Amyotrophic Lateral Sclerosis Cohort (MI-PALS) Study

NCT06119087
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Chronic Respiratory Failure, Airway Clearance Impairment, Neuromuscular Diseases
Interventions
Mechanical insufflation
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 8, 2026, 10:27 PM EDT
Not listed No phase listed Observational

Rehabilitation in SOD1 ALS Treated With Tofersen

NCT05725759
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Lou Gehrig Disease, Familial Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Motor Neuron Disease, Familial
Interventions
Rehabilitation
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 8, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis

NCT03945279
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIIB100, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 8, 2026, 10:27 PM EDT
Recruiting Not applicable Interventional

Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)

NCT06094205
View directory record Official record
Conditions
Anarthria, Dysarthria, Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked-in Syndrome, Muscular Dystrophies
Interventions
BrainGate Neural Interface System
Device
Lead sponsor
Leigh R. Hochberg, MD, PhD.
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 8, 2026, 10:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cortex Changes in Real/Imagined Movements in Amyotrophic Lateral Sclerosis (ALS)

NCT00809224
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 8, 2026, 10:27 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

NCT05395624
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
Interventions
18F-OP-801
Drug
Lead sponsor
Ashvattha Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
3
States / cities
San Francisco, California • Stanford, California • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 8, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT01786603
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Rasagiline, Placebo
Drug
Lead sponsor
Richard Barohn, MD
Other
Eligibility
21 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
Phoenix, Arizona • Irvine, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 8, 2026, 10:27 PM EDT
Completed Not applicable Interventional Results available

Study of Standard Noninvasive Positive Pressure Ventilation (NIPPV) and Low Expiratory Pressure NIPPV in ALS Patients

NCT01154283
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)
Device
Lead sponsor
Kirsten Gruis
Other
Eligibility
19 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 8, 2026, 10:27 PM EDT